171 related articles for article (PubMed ID: 34622876)
21. Low Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Correlate of Immune Infiltrates in Breast Cancer.
Yi W; Shen H; Sun D; Xu Y; Feng Y; Li D; Wang C
Med Sci Monit; 2021 Dec; 27():e934522. PubMed ID: 34880202
[TBL] [Abstract][Full Text] [Related]
22. LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
Zhu X; Chen D; Sun Y; Yang S; Wang W; Liu B; Gao P; Li X; Wu L; Ma S; Lin W; Ma J; Yan D
BMC Cancer; 2023 Feb; 23(1):120. PubMed ID: 36747161
[TBL] [Abstract][Full Text] [Related]
23. CCDC68 predicts poor prognosis in patients with colorectal cancer: a study based on TCGA data.
Zhang W; Xu TT; An ZT; Wei LF; Gu C; Li H; Tian YZ
J Gastrointest Oncol; 2022 Apr; 13(2):657-671. PubMed ID: 35557589
[TBL] [Abstract][Full Text] [Related]
24. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
25. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of OTX2-AS1 is Associated With Immune Infiltration and Predicts Prognosis of Gastric Cancer.
Han QL; Cui Z; Wang Q; Pang F; Li D; Wang D
Technol Cancer Res Treat; 2023; 22():15330338231154091. PubMed ID: 36740995
[TBL] [Abstract][Full Text] [Related]
27. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
[TBL] [Abstract][Full Text] [Related]
28. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
29. LncRNA FOXP4-AS1 serves as a biomarker for nasopharyngeal carcinoma diagnosis and prognosis.
Yao L; Wang T; Wang X
3 Biotech; 2021 Jan; 11(1):25. PubMed ID: 33442523
[TBL] [Abstract][Full Text] [Related]
30. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
31. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
32. LncRNA MSC-AS1 Is a Diagnostic Biomarker and Predicts Poor Prognosis in Patients With Gastric Cancer by Integrated Bioinformatics Analysis.
Yang W; Ge F; Lu S; Shan Z; Peng L; Chai J; Liu H; Li B; Zhang Z; Huang J; Hua Y; Zhang Y
Front Med (Lausanne); 2021; 8():795427. PubMed ID: 34926534
[TBL] [Abstract][Full Text] [Related]
33. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
34. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: an independent prognostic factor.
Chu ZP; Dai J; Jia LG; Li J; Zhang Y; Zhang ZY; Yan P
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8145-8150. PubMed ID: 30556852
[TBL] [Abstract][Full Text] [Related]
36. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
[TBL] [Abstract][Full Text] [Related]
37. LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.
Chen T; Zhu C; Wang X; Pan Y
Can J Gastroenterol Hepatol; 2021; 2021():8323487. PubMed ID: 34336727
[TBL] [Abstract][Full Text] [Related]
38. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of SIRT3-related nomogram predictive of overall survival in patients with serous ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
J Ovarian Res; 2019 May; 12(1):47. PubMed ID: 31113446
[TBL] [Abstract][Full Text] [Related]
40. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
Huang C; Cui H; Lang X; Zhao F
J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
